Data Sheet 1_Immune-inflammation index as prognostic markers in metastatic castration-resi

A systematic review and meta-analysis of 36 studies involving 10,325 patients with metastatic castration-resistant prostate cancer (mCRPC). The research, conducted by Zitong Qin and registered in PROSPERO, analyzes the prognostic value of blood-derived immune-inflammatory indices. It was last updated in April 2026 and is available as a PDF document.

Use Cases

• Evaluating the association between neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in mCRPC based on the reported pooled hazard ratios.
• Assessing the prognostic value of platelet-to-lymphocyte ratio (PLR) for progression-free survival (PFS) based on the meta-analysis results.
• Investigating the relationship between systemic immune-inflammation index (SII) and survival outcomes based on the reported hazard ratios.
• Comparing the prognostic performance of lymphocyte-to-monocyte ratio (LMR) with other indices based on the systematic review findings.

Strengths

• The analysis is based on 36 studies and 10,325 patient records, providing a substantial evidence base.
• Follows PRISMA 2020 guidelines and is registered in PROSPERO (CRD420261291003), indicating a structured methodology.
• Reports specific pooled hazard ratios with 95% confidence intervals for multiple indices (e.g., NLR HR=1.77 for OS).

Limitations

• The dataset is a 107.2 KB PDF document; the underlying structured data (e.g., individual study data) is not provided.
• Row count and column-level documentation for any underlying data are unknown.
• Some subgroup analyses were limited by small numbers, as noted in the description.

Provenance

Source

figshare, author Zitong Qin

Collection Method

Systematic review and meta-analysis of studies from Embase, PubMed, Web of Science, and Cochrane Library up to May 2025.

Time Range

Studies from database inception until May 2025.

Freshness

Last updated 2026-04-27 04:14:39